In the face of an increasingly growing incidence of dementia, VCID being a main contributor, we conclude that targeting WM inflammation and, specifically, Gal-3 microglial cells, may represent a promising therapeutic avenue, as proposed in other models of demyelination accompanied with cognitive deficits50,51. The gene discussed is LGALS3; the disease is dementia.